Welcome to Our Website!

The AIDS Malignancy Consortium (AMC) is a National Cancer Institute-supported clinical trials group founded in 1995 to support innovative trials for AIDS-related cancers. The AMC is composed of 36 Clinical Trials Sites worldwide, five Working Groups, an Administrative Office, a Statistical Office, and an Operations and Data Management Office. Collectively, these components develop and oversee the scientific agenda, manage the groups’ portfolio of clinical trials and other scientific-based studies, and help to develop new protocols. The AMC mission is to investigate new treatment and prevention interventions for malignancies in people living with HIV and to study the pathobiology of these tumors in the context of clinical trials.

Four of the working groups deal with the cancers that affect HIV-positive patients—Kaposi’s Sarcoma, Lymphoma, Human Papillomavirus-related Cancers (for example, anal and cervical cancers), and Non-AIDS Defining Cancers (for example, lung cancer, head and neck cancer, liver cancer). The Laboratory Working Group oversees the Central Laboratories of the AMC and develops laboratory studies to answer important scientific questions related to cancer in HIV-positive patients. In addition, all of the groups within the AMC are working to expand the AMC globally and to conduct clinical trials for AIDS-related cancers in diverse patient populations.

We invite you to explore the AMC Website, and we actively seek your input/feedback.

Health News

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV Working Group
The findings of the AMC Lymphoma Working Group have influenced ASCO and National Comprehensive Network Guidelines.

Human Papillomavirus Vaccine Proves Effective in Women With HIV
A study of HIV-infected women in the United States, Brazil, and South Africa has found that the quadrivalent HPV vaccine was safe and immunogenic against HPV types 6, 11, 16, and 18, even if the women had had HIV for years. The study by Kojic et al is published in Clinical Infectious Diseases.

FDA Advisory Committee Unanimously Recommends HPV Test as Primary Screening Tool for Detection of Women at High Risk for Cervical Cancer
The U.S. Food and Drug Administration Microbiology Devices Panel of the Medical Devices Advisory Committee has recommended unanimously that the benefits of the cobas human papillomavirus test outweigh the risks as a first-line primary screening tool to assess the risk of cervical cancer in women aged 25 years and older. The panel also voted unanimously that the test is safe and effective for the proposed indication for use.